Interv Akut Kardiol 2012; 11(3-4): 138-142

Markers of myocardial ischemia for clinical use?

Jaroslav Dušek¹, Josef Šťásek¹, Josef Bis¹, Miroslav Brtko², Jan Vojáček¹, Pavel Polanský², Martina Vašatová³, Dušan Černohorský⁴

¹ I. interní kardioangiologická klinika LF UK a FN Hradec Králové

² Kardiochirurgická klinika LF UK a FN Hradec Králové

³ Ústav klinické biochemie a diagnostiky LF UK a FN Hradec Králové

⁴ Klinika gerontologická a metabolická LF UK a FN Hradec Králové

New biomarkers of myocardial ischemia have the potential to improve diagnostic accuracy of acute coronary syndrome (ACS) within

a shorter time interval after symptom onset. This paper reviews the avaiable information and evaluates the evidence for use of new

biomarkers in diagnosing ACS in patients presenting with chest pain or symptoms suggestive of cardiac ischemia to the emergency

department or chest pain unit. Ischemia modified albumin, measured using the albumin cobalt binding test, is currently the most promising

biomarker for early detection of ischemia before the onset of irreversible cardiac injury. Fatty acid bindig protein, B-type natriuretic

peptide, copeptin, and matrix metalloproteinase-9 are other promising biomarkers. According this progress, we have to conclude, that

there is anadequate evidence suggesting the routine testing of these markers in isolation, however these biomarkers have the potintial

to improve the sensitivity of diagnosing ACS when combined with cardiac-specific troponin.

Keywords: myocardial ischemia, marker

Published: May 11, 2012  Show citation